These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 4764560)

  • 21. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 22. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R
    Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
    [No Abstract]   [Full Text] [Related]  

  • 23. [Therapy of parkinsonism using a combination of L-dopa and decarboxylase inhibitor].
    Völler GW; Muschard F
    Med Welt; 1973 Apr; 24(17):705-7. PubMed ID: 4750934
    [No Abstract]   [Full Text] [Related]  

  • 24. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A
    Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
    [No Abstract]   [Full Text] [Related]  

  • 26. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 27. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H
    Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980
    [No Abstract]   [Full Text] [Related]  

  • 28. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL; Ringel SP
    Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
    [No Abstract]   [Full Text] [Related]  

  • 29. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 30. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J; Markus E
    Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 32. MK 486 and levodopa in treatment of Parkinsonism.
    Lieberman AN; Derby BM; Feigenson J; Goodgold A; Nesbitte J; Resurreccion EC; Valdivia F
    Dis Nerv Syst; 1973; 34(4):167-71. PubMed ID: 4711885
    [No Abstract]   [Full Text] [Related]  

  • 33. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 34. [Accomplishment of the treatment and evaluation of treatment alternatives in parkinsonism].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2119. PubMed ID: 4773985
    [No Abstract]   [Full Text] [Related]  

  • 35. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

  • 37. [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].
    Schneider E; Fischer PA; Jacobi P; Maxion H
    Arch Psychiatr Nervenkr (1970); 1973 Mar; 217(1):95-112. PubMed ID: 4695662
    [No Abstract]   [Full Text] [Related]  

  • 38. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
    Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J
    Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1969 Dec; 197(1):85-100. PubMed ID: 5364658
    [No Abstract]   [Full Text] [Related]  

  • 40. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.